NOXXON Announces Trading Halt on Euronext Growth Paris Ahead of Trial Data Publication at the ESMO ImmunoOncology Congress

NOXXON Announces Trading Halt on Euronext Growth Paris Ahead of Trial Data Publication at the ESMO Immuno-Oncology Congress

Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), anno...

More From BioPortfolio on "NOXXON Announces Trading Halt on Euronext Growth Paris Ahead of Trial Data Publication at the ESMO Immuno-Oncology Congress"